Vitalhub Hits $100M ARR with 33% Revenue Jump
Vitalhub reports $31.7M in Q2 revenue, crossing the $100M annual recurring revenue milestone while maintaining a debt-free balance sheet.
Key points
- Vitalhub reported Q2 2026 revenue of $31.7 million, a 33% year-over-year increase, with ARR exceeding $100 million.
- The company holds $136.5 million in cash and investments with no debt, supporting its ongoing M&A strategy.
- Adjusted EBITDA margin reached 26%, while an AI roadmap aims to boost transcription and protocoling revenue by 2027.
Vitalhub (TSX:VHI) reported second-quarter 2026 results that marked a significant inflection point for the healthcare software provider. Total revenue climbed 33% year-over-year to $31.7 million, driven by a 10% organic growth rate that pushed annual recurring revenue past the $100 million threshold. The company closed the quarter with $101.5 million in ARR, a figure that underscores the stability of its term license, maintenance, and support segments, which accounted for $24.5 million of the total quarterly intake.
Profitability metrics remained robust despite a slight contraction in gross margin from 81% to 79%. Adjusted EBITDA reached $8.2 million, representing a 26% margin that improved sequentially. Management attributed this efficiency to operational synergies and the integration of recent acquisitions, including Buddy Healthcare, which expanded the firm’s digital solutions portfolio in the UK and Canadian markets. According to Benzinga, the company’s financial position is further strengthened by a debt-free balance sheet holding $136.5 million in cash and investments.
Acquisitions drive portfolio expansion
The strategic acquisition of Buddy Healthcare is central to Vitalhub’s current growth trajectory. This move enhances the company’s integration capabilities and broadens its digital health offerings, specifically targeting the UK and Canadian healthcare systems. Management indicated that these additions are designed to create cross-selling opportunities and expand the patient care coordination platform across regions, including potential entry into the US market.
Vitalhub is also focusing on integrating prior acquisitions, Induction and Novari, to maximize value. The company’s M&A strategy remains active, supported by a cash reserve exceeding $120 million. To balance capital allocation between buybacks and acquisitions, Vitalhub initiated a normal course issuer bid to repurchase shares, signaling confidence in its long-term value proposition while maintaining liquidity for strategic deals.
AI roadmap targets 2027 revenue
Looking ahead, Vitalhub has outlined an AI roadmap that includes new protocoling solutions and the integration of artificial intelligence into transcription services. Management expects these technological advancements to positively impact revenue by the end of 2027. These initiatives are part of a broader effort to modernize clinical workflows and improve data utility for healthcare providers.
UK market challenges persist
Despite strong overall performance, the company faces specific headwinds in the UK market. Some customers have suspended contracts due to the unresolved Palantir situation, creating temporary uncertainty in that region. Management remains optimistic that these issues will be resolved, citing ongoing growth opportunities and the resilience of the broader healthcare sector. The firm continues to monitor the situation closely while executing its integration plans.
